Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

Web Exclusives - FDA Approvals, Select Drug Profiles

On March 31, 2021, the FDA accelerated the approval of a new indication for isatuximab-irfc (Sarclisa; sanofi-aventis), a CD38-directed antibody, in combination with carfilzomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy. Isatuximab was initially approved by the FDA in 2020, in combination with pomalidomide and dexamethasone, for adults with relapsed or refractory multiple myeloma who have received ≥2 therapies, including lenalidomide and a proteasome inhibitor.

The FDA approval of isatuximab in combination with carfilzomib and dexamethasone was based on the IKEMA study, a multicenter, multinational, randomized, open-label, 2-arm, phase 3 clinical trial of patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy. The study included 302 patients who were randomized in a 3:2 ratio to isatuximab plus carfilzomib and dexamethasone or to carfilzomib and dexamethasone.

The main efficacy outcome was progression-free survival (PFS). The median PFS was not reached (NR) in the isatuximab plus carfilzomib and dexamethasone arm versus 20.27 months (95% confidence interval, 15.77-NR) with carfilzomib and dexamethasone alone (P = .003), a 45% risk reduction of disease progression or death with the addition of isatuximab.

The most common (≥20%) adverse reactions with the isatuximab-based combination were upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain. The most common (≥80%) hematology laboratory abnormalities were decreased hemoglobin, decreased lymphocytes, and decreased platelets.

Related Items
FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Approved Xdemvy, First Treatment for Demodex Blepharitis
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Accelerated the Approval of Veopoz, First Drug for the Treatment of Patients With CHAPLE Disease
Web Exclusives published on September 9, 2023 in FDA Approvals
FDA Accelerated the Approval of Sohonos, First Drug for the Treatment of Fibrodysplasia Ossificans Progressiva
Web Exclusives published on September 9, 2023 in FDA Approvals
Last modified: August 30, 2021
© Amplity Health. All rights reserved.